Author: Dr. Alexis LeVee, City of Hope At the ASCO 2024 conference, Dr. Alexis LeVee from City of Hope presented a pivotal Phase 1b clinical trial that explores the combination of CDK4/6 inhibitors and PD-1 inhibitors with endocrine therapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2- mBC). This study investigates how these … Continue reading ASCO 2024: Palbociclib, Pembrolizumab, & Endocrine therapy in HR+/HER2- locally advanced or metastatic breast cancer (MBC) – Alexis LeVee, MD – City of Hope